



De

PATENT
ATTORNEY DOCKET NO.: 056291-5173

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:)
Ann-Margret LINDQVIST)
Application No.: 10/502,355) Group Art Unit: 1615
Filed: February 4, 2005) Examiner: Unassigned
FOR: USE OF BENZOTHIAZEPINES HAVING)
ACTIVITY AS INHIBITORS OF ILEAL)
BILE ACID TRANSPORT FOR REDUCING)
CHOLESTEROLEMIA)

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop ____
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Date: April 13, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(b)

Attached is a Form PTO-1449 listing the enclosed foreign patent documents.

Attached is a Form PTO-1449 listing the enclosed foreign patent documents.

Copies of any U.S. patent documents are not enclosed.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.

Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 056291-5173 and proceed to consider this IDS.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.


Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP. 609 along with an early action on the merits of this application are earnestly solicited.

Except for issue fees payable under 37 C.F.R. §1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP


Date: April 13, 2005
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk

By:



Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

| | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|----------------------|
| FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT | Attorney Docket No. | Client Ref. |
| | 056291-5173 | |
| | Applicant: Ann Margaret Lindqvist | |
| | Appln. No.: 10/502,355 | |
| Filing Date: February 4, 2005 | | |
| Examiner: Unassigned | | Group Art Unit: 1615 |



Date: April 13, 2005

U.S. PATENT DOCUMENTS

| Examiner's Initials* | Document Number | Date MM/YYYY | Name (Family Name of First Inventor) | Class | Sub Class | Filing Date (if appropriate) |
|----------------------|-----------------|-----------------|-----------------------------------------|-------|-----------|---------------------------------|
| AR | | | | | | |
| BR | | | | | | |
| CR | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | Document Number | Date MM/YYYY | Country | Inventor/Applicant Name | English Abstract | | Translation Readily Available | |
|----|----|-----------------|-----------------|---------|-------------------------|------------------|----|-------------------------------|----|
| | | | | | | Enclosed | No | Enclosed | No |
| | DR | 00/01687 | 01/2000 | WO | Lee et al. | | | | |
| | ER | 00/38725 | 07/2000 | WO | Keller et al. | | | | |
| | AR | 00/38726 | 07/2000 | WO | Keller et al. | | | | |
| | FR | 00/38727 | 07/2000 | WO | Keller et al. | | | | |
| | BR | 00/38728 | 07/2000 | WO | Keller et al. | | | | |
| | CR | 00/38729 | 07/2000 | WO | Keller et al. | | | | |
| | DR | 00/47568 | 08/2000 | WO | Tollefson et al. | | | | |
| | GR | 00/61568 | 10/2000 | WO | Frick et al. | X | | | X |
| ** | HR | 00/62810 | 10/2000 | WO | Abrahamsson et al. | | | | |
| | ER | 01/60807 A1 | 08/2001 | WO | Liu et al. | | | | |
| | IR | 01/66533 A | 09/2001 | WO | Starke et al. | | | | |
| | FR | 01/68096 A2 | 09/2001 | WO | Keller et al. | | | | |
| | GR | 01/68637 A2 | 09/2001 | WO | Babiak et al. | | | | |

| | | | | | | | | | |
|--|----|---------------------------------------------------------------------------------------------------------------------|--|--|--|--|--|--|--|
| | JR | Govers et al., Journa of Lipid Research, 35(5), 1994, pp. 741-748 | | | | | | | |
| | KR | Higaki et al., Atherosclerosis, Thrombosis, and Vascular Biology, 18(8), Aug. 1998, pp. 1304-1311 | | | | | | | |
| | LR | Ishibashi et al., Journal of Clinical Investigation, 92(2), Aug. 1, 1993, pp. 883-893, XP000574730, ISSN: 0021-9738 | | | | | | | |
| | MR | Lewis et al., Journal of Lipid Research, (36), 1995, pp. 1098-1105 | | | | | | | |
| | NR | Plump et al., Cell, (71), Oct. 16, 1992, pp. 343-353 | | | | | | | |
| | OR | Schiller, Alimentary Pharmacology and Therapeutics, 15(6), 2001, pp. 749-763 | | | | | | | |
| | PR | Sprong et al., J Nutrition (US), 2002, 132(6), pp. 1269-1274 | | | | | | | |
| | QR | Van Tilburg et al., Gastroenterology, 98(1) 1989, pp. 25-32 | | | | | | | |
| | RR | Welberg et al., Scandinavian J. Gastroenterology Suppl Norway, 188, 1991, pp. 52-59 | | | | | | | |

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| Examiner | Date Considered: |
| *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. | |